Navigation Links
Shire Completes Acquisition of Advanced BioHealing, Inc.
Date:6/28/2011

DUBLIN, June 28, 2011 /PRNewswire/ --


 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the satisfaction of the closing conditions, including the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the acquisition of Advanced BioHealing, Inc. ("ABH"), as first announced on May 17, 2011, has been completed.

The Advanced BioHealing business becomes part of Shire's Specialty Pharmaceuticals business, led by Mike Cola, and will leverage biologic manufacturing expertise from Shire's Human Genetic Therapies business. Kevin Rakin, Chief Executive Officer of Advanced BioHealing, will continue to lead this business within the Shire organization.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.


"SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations Eric Rojas (erojas@shire.com) +1-781-482-0999 Sarah Elton-Farr (seltonfarr@shire.com) +44(0)1256-894157 Media Jessica Mann (jmann@shire.com) +44(0)1256-894-280 Matthew Cabrey (mcabrey@shire.com) +1-484-595-8248


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Menopause Drugs Price Analysis and Strategies - 2016, provides drug ... answers the following questions: What are the ... positioned in the Global Menopause market? What are the ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... social media management, corporate communications, SEO and cause marketing, is opening an office ... New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... PHILADELPHIA (PRWEB) , ... February 23, 2017 , ... ... risk and uncertainty in clinical trials, today announced that Premier Research, a leading ... management solution. , Clinical trials are becoming increasingly complex, due in part to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez ... has also continued to spiritually evolve, which is the purpose of everyone in this ... Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand one’s ...
Breaking Medicine News(10 mins):